FR2841101A1 - Oral administration of taurine and hypotaurine for the prevention and treatment of hair loss - Google Patents

Abstract

The use of taurine and/or hypotaurine and their salts in oral compositions for the prevention and treatment of aging of the pilosebaceous unit and/or alopecia. ACTIVITY : Endocrine-Gen. MECHANISM OF ACTION : Hair follicle alteration regulator; proline incorporation is reduced whilst leucine incorporation is unaffected. Two groups of 36 women aged 18 - 40 years having fine, limp and seborrheic hair were treated either with a composition as described or a placebo based on maltodextrin. The active formulation contained, per unit dose, taurine (159 mg), green tea extract (30 % catechins; 375 mg), grapeseed extract (40 % procyanidin oligomers, 20% catechins; 150 mg), zinc (as zinc sulfate; 15 mg). The number of hairs removed by three sweeps of the comb were counted after 0, 3, and 6 months, and the results are shown in the figure. After six months the number of hairs removed from the treated subjects averaged 40.5, whilst the number from untreated subjects was 56.7.

Description

28411 01

  The present invention relates to the use of fatty acids in food supplements, for the prevention and treatment of functional disorders of the pilo-sebaceous unit, optionally in combination with taurine and / or hypotaurine and compositions dietary supplements comprising fatty acids, optionally in combination with taurine and a cosmetic process of

  treatment and prevention of these disorders.

  Some cutaneous changes occur with age, largely due to abnormal metabolism of androgens. These include the reduction of hair density during aging, the number and diameter of the hair rods decreasing. Especially in men, some subjects develop the phenomenon

of andro-genetic alopecia.

  In addition, these alterations of hair wind often accompanied

  alteration of the condition of the scalp, such as the abundant production of sebum.

  Hypersecretion sebaceous or seborrhee and its consequences, the acne for example, are frequently manifested at the time of puberty, but can continue in adulthood, especially in women, for

hormonal causes.

  Finally, in women, some anomaly of the pilositis such as the excessive growth of polls (beard, mustache, on the legs ...) appear with age. An exaggerated action of androgens can also

alter the barrier function.

  These three types of disorders can occur together,

  different degree, in the same individual.

  To fight against hypersecretion sebacee, local treatments have been proposed including isotretinoin, but this treatment is not

  not devoid of serious side effects.

  The use of anti-androgens against aiopecia and sebaceous hypersecretion has been advocated for systemic use. This type of treatment is

28411 01

  However, there are no serious side effects, especially on

sexual organs.

  WO 99/22728 describes many compounds whose

  fatty acids, in particular, for therapeutic uses.

  s The drugs have disadvantages related to the risks inherent to their use, insofar as the drugs of xenobiotic wind. In addition, the drugs generally have a very targeted spectrum of action, even as the causes of the alteration of the pilo unit.

sebacee multiple wind.

  The compositions for topical use have on their side the drawbacks related to local application: the alterations related to alopecia and to the disorders of the pi-sebaceous system are difficult to treat by topical treatment, especially when these are important areas

  Frequency of applications is daily.

  Thus, there is still a need for assets that can be used for the purpose, effective in the treatment of

  disorders of the pilo-sebaceous organism, and devoid of side effects.

  Surprisingly, the Applicant has demonstrated that extracts rich in fatty acids, used by vale vale, as a dietary supplement, have a beneficial activity on the disorders induced by a local excess of hormone androgen, at the level of the sebaceous pilo unit. Dietary supplements comprising fatty acids may in particular prevent the cutosterone activation of testosterone (intracrine), and the increase in the resulting sebaceous function, and this

  without any general effect on the genital tract or sexual functions.

  Thus, the invention relates to the use of fatty acids for the preparation of a dietary supplement useful in the treatment or prevention of disorders of the pilo-sebaceous unit. Wile concerns in particular the use of extracts rich in fatty acids in a food supplement, to prevent or reduce the hair loss induced by the

28411 01

  seborrhee, to prevent local androgenic activation, especially

  the impact of testosterone on the pilo-sebaceous unit.

  The pilosebacee unit has a hair follicle and its sebaceous glance. In addition, the present invention relates to the use of taurine eVou or homotaurine eVou homotaurin, or their acceptable salts, in combination with at least one fatty acid, for the preparation of a dietary supplement useful in the treatment and the prevention of

  alopecia, and for the amelioration of the state of the pilo-sebaceous unit.

  Indeed, taurine, hypotaurine, homotaurine or their acceptable salts may be according to the invention used in dietary supplements against the alteration of the perifollicular connective tissue and the stiffening of the conjunctive sheath. Hypotaurine, taurine, homomotaurine or their acceptable salts can be used to regulate the production and structure of collagen in cutaneous tissue, including non-pathological skin tissue, and in particular the tissue of the hair follicle conjunctive sheath. . The food supplements of the invention are thus useful

  to prevent miniaturization of the hair follicle.

  The combination of fatty acids and taurine, metabolites and analogues, allows the treatment and prevention in a wide spectrum of actions, a synergy between the components, and this without side effect

  on the synthesis of proteins on the one hand or the sexual sphere on the other.

  The present invention also relates to food supplement compositions comprising fatty acids, and possibly taurine eVou hypotaurine eVou lthomotaurine or their salts

acceptable for vale absorption.

  Finally, the invention relates to a cosmetic process for the treatment and prevention of alopecia eVou disorders of the pilosebacee unit by ingestion of dietary supplements comprising at least one fatty acid and possibly taurine eVou homotaurine eVou de

  Hypotaurine and their salts are acceptable for administration.

28411 01

  The invention will be better understood on reading the description

  detailed and following examples, and in view of the appended figure.

  Figure 1 shows the results of ingestion of fatty acids by

hamsters, in a CVO test.

  Fatty acids according to the invention are polyunsaturated fatty acids, that is to say all fatty acids with double bonds.

interrupted cis, cis-methyiene.

  The polyunsaturated fatty acids are defined according to the length of the carbon chain and the position of the double bond. The essential fatty acids are currently classified into two groups (co3 and c6) characterized by the position of the unsaturation closest to the group

terminal methyl.

  As fatty acids, it is possible to use, according to the invention, the fatty acids of two families of essential polyunsaturated fatty acids of the families of fatty acids n-6 and n-3, comprising between 18 and 22 carbon atoms,

  as well as their esters and mixtures.

  For the polyunsaturated fatty acids of the n-6 series, termed omega-6, there may be mentioned the first, linoleic acid, having 18 carbon atoms and two unsaturations: (18:26), and the y-acid linolenic (18: 3c6)

  is also a particularly interesting fatty acid according to the invention.

  The sources of γ-linolenic acid will be chosen from vegetable oils (oil ofion, borage, blackcurrant pep and

  hemp), Spirulina extracts, Spirula. maxima and S. platensis.

  For polyunsaturated fatty acids of the n-3 series, termed "omega-3", the first is alpha-linolenic acid (18: 3co3); Stearidonic acid (C18: 4 n-3) is also a particularly fatty acid

interesting in the invention.

  Vegetable oils of nuts (Juglans regia) and soy (Glycina max) for example, wind rich in polyunsaturated fatty acids of the serie

  omega 3 as well as fish oils.

28411 01

  The polyunsaturated fatty acids c3 are found, via the chain

  zooplanton, crustaceans / molluscs and fish.

  Fish oils are the main industrial source of EPA (eicosapentacnoc acid = 20: 5 c3) and DHA (docosahexaenoc acid = 22: 6 c3). However, microalgae biomass can also be a raw material for co3 extraction. The nutritional quality of microalgae can be improved by a judicious choice of strains and a metabolic orientation related to

culture conditions.

  The interest for microalgae is all the greater

  synthesize fatty acids, such as EPA and DHA.

  Preferably, linoleic acid, y-linolenic acid, linolenic acid, stearidonic acid, crocetin and 5,8,11,14 eicosatetrainoque acid and mixtures thereof or extracts thereof are used. Thus, the fatty acid (s) of the extract (s) may be used alone or in mixtures. The daily doses of fatty acids recommended according to the invention range from 0.5 to 3500 mg / day, preferably from 5 to 1500 mg / day. Wiles are, for n-3 fatty acids between 0.5 and 2500 mg / day, preferably 360 mg / day, and for n-6 fatty acids between 0.5 and

  2600 mg / day, preferably 5 to 1200 mg / day.

  As a regulating active agent of the alterations of the hair follicle and / or anti-collagen according to the invention, it is possible to use taurine eV or hypotaurine, which is a metabolite eV or homotaurine, which is an analogue of taurine (acid 3-amino propane sulfonic acid). It is also possible to use their acceptable salts in such vales compositions, for example their alkaline or alkaline earth salts, in particular their salts.

  magnesium, manganese, iron 11 or zinc.

  According to the invention, taurine, hypotaurine or homotaurine are used in combination with the fatty acid (s) at daily doses of 0.5 to 4000 mg per day, preferably 10 to 500 mg / day. mg per day. Of

28411 01

  Again, the preferred daily dose is about 50 to 150 mg

taurine equivalent.

  For the ingestion of assets or assets, many forms of supplementation are possible. Their formulation is carried out by the usual methods for producing dragees, capsules,

  gels, emulsions, tablets, capsules or drinkable ampoules, for example.

  Nevertheless, the active (s) according to the invention can be incorporated in all other forms of food supplements, for example food bars, fortified foods, compact powders or not. The powders can be diluted with water, in soda, dairy products

  or soy derivatives, or be incorporated into food bars.

  The dietary supplement compositions comprise 0.01% by weight of fatty acids and 0.01% to 30% by weight of taurine, e.g. homotaurine, hypotaurine and / or acceptable salts thereof.

Excipient.

  The active ingredients can be formulated with the usual components for such food supplements, namely in particular aqueous fatty components, humectants, thickeners, preservatives, texture agents, flavoring eVou, antioxidants, preservatives and

  common dyes in the field of food.

  The formulating agents and excipients for food supplements are known in this field and are not here discussed.

detailed description.

  These compositions may comprise, in combination with taurine eVou hypotaurine eVou homotaurine or their salts, one or more other active agents such as in particular polyphenols and vitamins and

  antioxidants, possibly in the form of complexes.

  As active agents, mention may be made of zinc and its salts, vitamins B5, B6, B8, C, E, or PP, p-carotene and carotenodes, and garlic extracts in the form of sulphide. allyle or ajoen for example the

28411 01

  selenium, curcumin, curcuminodes, niacin, acid

lithospermic, adenosine.

  In particular, it is possible to use an antioxidant complex comprising vitamins C and E, zinc or its salts, selenium and at least one carotenoid, in particular a carotenode chosen from among

  carotene, lycopene, zeaxanthin and lutein.

  An antioxidant complex having, for example, from 150 mg of vitamin C is preferred for 80 to 120 μg of selenium, 20 to 50 mg of

  vitamin E, 10 to 40 mg of zinc and 3 to 10 mg of B-carotene.

  As the polyphenol according to the invention, it is possible to use any dietary polyphenol. These compounds are generally derived from plants, and their structures are classified according to the nature of the hydrocarbon skeleton (Laura Bravo Nutrition Review 1998 56 pp 317-333, Scalbert A. williamson

GJ Nutr 2000 130 2073s 2085S).

  According to the invention, the term "polyphenols" is particularly understood to mean flavonode-type compounds, that is to say flavones, flavonols, isoflavones, anthocyanins, flavanols, proanthocyanidines and flavanones, and stilbenes. The main flavanols will be chosen from catechines, gallocatechines. Procyanidines produce flavonol polymers present in the form of low-grade polymer blends. They

  may be associated with catechins in plant extracts.

  Preferably, polyphenols or polyphenol mixtures selected from catechin, epicatechine, epigallocatechin 3-Ogallate, epigallocatechine, epicatechin-3-gallate, procyanidines are used.

and proanthocyanidins.

  These contributions in polyphenols can be fan's from compounds

  isolated and / or from plant extracts and their mixtures.

  According to the invention, it is possible to use plant extracts which can provide these polyphenols and their polymers. More particularly, the catechines wind very abundant in the tea (Camellia Simensis), and the

28411 01

  grapes (Vitis Vinifera) and other fruits (apple, pear, pine cone (Pinus Maritima)), beverages (wine, beer, tea), chocolate (Theobroma Cacao) are sources that may constitute catechin intakes according to [' invention. These polyphenols may be used alone or in the form of mixtures, and may be ingested under different forms of nutritional supplements (sucrose, gels, soluble powders, capsules,

capsules, fortified foods ...).

  These dietary polyphenols can be used at doses of

  0.5 to 1000 mg / day, preferably 20 to 300 mg / day.

  By way of example, mention may be made of a grape seed extract of 40% OPC, a red wine extract containing 30% of total polyphenols and / or an extract

green tea has 30% catechines.

  The procyanidin oligomers (OPC) can be used at doses of 0.5 to 1000 mg / day, preferably 250 to 250 mg / day. They can be brought by an extract of grape pepins, which one dose according to its title OPC. For example, for a grape seed extract with 40% OPC, ci

  above, it is used at a dose of 150 mg / day, or 60 mg / day OPC.

  On the other hand, catechins can be used at doses of 0.5 to 1000 mg / day, preferably 20 to 300 mg / day. Wiles can be provided for example by a 30% green tea extract of catechins, the dose

  of extract then being of the order of 375 mg / day, ie 112.5 mg / day of catechins.

  As examples of daily doses of polyphenols, mention may be made of daily doses of a red wine extract rich in polyphenolic components (600 mg of red wine extract powder: 12 mg OPC / person / day or 18 mg total polyphenols) daily doses of a grape pep extract rich in polyphenolic components (300 mg of red wine extract powder: 18 mg OPC / person / day or 27 mg total polyphenols), daily doses rich green tea extract in polyphenolic components (225 mg green extract powder:

67.5 mg catechins / day).

28411 01

  The active agents according to the invention may furthermore be combined with known anti-hair loss agents, and in particular compounds which improve their activity on the condition of the pilo-sebaceous unit and the braking of hair loss, such as more particularly, the following compounds: - nicotinic acid esters, including more particularly C3-C6 alkyl nicotinates and especially methyl or hexyl nicotinate, benzyl nicotinate or tocopherol; steroidal and non-steroidal anti-inflammatory agents well known in the state of the art and in particular hydrocortisone, its salts and derivatives, niflumic acid; Retinofids, and more particularly retinolous t-trans acid, also known as tretinoin, isotretinol, retinol or vitamin A and its derivatives, such as acetate, palmitate or propionate, motretinide, etretinate, retinoate zinc t-rans; antibacterial agents chosen more particularly from macrolides, pyrazones and tetracyclines and especially erythromycin; calcium antagonists such as Cinnarizine and Diltiazem; hormones, such as estriol or analogs or thyroxine and its salts; antiandrogen agents, such as oxendolone, spironolactone, diethylstilbestrol; OH radical scavengers, such as dimethylsulfoxide; esterified oligosaccharides, such as those described in EP-A-0 211 610 and EP-A-0064012; hexosaccharic acid derivatives, such as those described in EP-A-0 375 388, in particular glucosaccharic acid; glycosidase inhibitors, such as those described in EP-A-0 334 586, in particular D-glucaro 1, 5-lactam;

28411 01

  inhibitors of glycosaminoglycanases and proteoglycanases, such as those mentioned in EP-A-0 277 428, in particular L-galactono 1,4-lactone; tyrosine kinase inhibitors, such as those described in EP-A 0 403 238, in particular 1-amido-1-cyano- (3,4-dihydroxyphenyl) ethylene. It is also possible to associate with the active ingredients of the invention, optionally in admixture with the others, compounds such as diazoxide corresponding to 3-methyl-7-chloro [2H] benzothiadiazine-1,2,4-dioxide; Spiroxazone or 7- (acetylthio) -4 ', 5'-dihydrospiro [androst 4 en-17,2' (3'H) furan] 3 one; phospholipids such as lecithin; Salicylic acid and its derivatives described in particular in French Patent No. 2,581,542, and more particularly salicylic acid derivatives bearing an alkanoyl group having 2 to 12 carbon atoms in the 5-position of the benzene ring, acids hydroxycarboxylic or cetocarboxylic acids and their esters, lactones and their corresponding salts; Anthralin, eicosatrlyonic acid-5, 8.1 1, their esters and amides, minoxidil and its derivatives, the compounds described in

  EP 353,123, EP 356,271, EP 408,442, EP 522,964, EP 420,707,

  EP 459,890, EP 519,819, US 4,139,619 and US 459,812.

  The above compounds are incorporated into the dietary supplements as long as their use as food supplement is possible, and their formulation compatible with that of the active ingredients of the invention. These additional actives are used according to the invention at doses compatible with their use as food supplements. Thus, for some compounds, it will be preferable to use them by

  topical, in addition to the dietary supplements of the invention.

  The cosmetic process according to the invention is covered by a daily consumption, for example, of food supplements according to the invention may be in the form of capsules, gels, dragees, emulsions, tablets, capsules, drinkable bulbs, powder, fortified foods. in adequate quantity or number, according to their form so that the

28411 01

  the fatty acids are ingested at doses of 0.5 to 5400 mg per day,

  preferably from 5 to 1600 mg per day.

  By way of example, for gamma linolenic acid, which may be provided by blackcurrant seed oil, doses of the order of 10 to 3000 mg / day, preferably 50 to 500 mg / day, may be provided. 1000mg / day. Taurine eVou lthypotaurine eVou the homotaurine associated, eVou

  their salts can, for their part, be ingested according to the above dosages.

  EXAMPLE OF EVIDENCE OF THE ACTIVITY.

  1 / CVO test: In order to highlight the activity of these compounds, a test for the detection of activity at the level of a specific pilosebaceous formation was

uses: the CVO test.

  The CVO (costo-vertebral organ) of the Hamster is a cutaneous region rich in pilosebaceous units (hair follicles and their sebaceous glances). The size of this formation is increased by the action of testosterone. The test (Liao S & al., Arch Dermatot Res 2001 Apr: 293 (4): 200-205) consists in determining the anti-androgenic action of compounds on the CVO, that is to say to determine whether the compounds

  prevent the action of testosterone.

  In this test, the black currant oil at 10% in food for 85 days is given to male hamsters. It can be seen that this nutritional supplement prevents the increase in the size of the induced CVO.

by testosterone.

  Thus, in Figure 1, the dotted curve represents the change in CVO size (mm2) in control animals, without supplementation, during the experiment Days in abscissa: there is an increase in the size of the induced CVO by testosterone. The solid line represents the evolution of CVO size in animals with supplementation:

  this increase is reduced to practically zero.

28411 01

  2 / Absence of side effects on the sexual sphere: The Hamsters take this nutritional supplement by vale vale, and it has been noted the repercution anti-androgen action not only on the CVO, but also on the sexual organs in animals males: it has been found that this nutritional supplement does not alter the weight

  seminal vesicles and prostate.

  EXAMPLE OF HIGHLIGHTING THE ACTIVITY OF TAURINE

  A study was carried out to evaluate, by a screening method, the effects of the compounds on the fibroblast growth and the synthesis of the major components of the extracellular matrix. The technique has made it possible to study and evaluate the interest of taurine on this cellular metabolism (T. Shigematsu et al., Biochimica and Biophysica Acta

1200 (1994) 79-83).

  A pool of normal human dermal fibroblasts (NHDF pool PF2, used in the eighth passage) was cultured under standard conditions in a medium: DMEM, 2mM L-glutamine, penicillin / streptomycin 50

  IU / ml / 50 g / ml, 0.5% fetal calf serum.

  Taurine was tested at concentrations of 10 mM and 1 mM,

  in a sterile culture medium, against an untreated control witness.

  Fibroblast incorporation results of thymidine, proline and leucine appear in the following Table I which shows the effect of taurine on the incorporation of thymidine, proline and leucine.

  in macromolecules neosynthesized by NHDFs in in vitro culture.

  The figures in bold are those for which there is significant variation (statistic sign for statistical significance: p <0.005). The results wind

  expressed as a percentage of control.

28411 01

Table 1

  Thymidine Proline Leucine% control sign.stat% control sign.stat% control sign.stat Taurine 1 mM 89 p> O.05 88 p <o.o1 100 p> O.05 Taurine 10 mM 90 p> o.O5 87 p It appears that taurine, in both treated concentrations, did not significantly alter S thymidine fibroblast incorporation, indicative of cell proliferation or growth. leucine, representative of non-collagenic protein synthesis; on the other hand, taurine inhibited proline fibroblast incorporation of

significantly.

  In the description and in the following examples, unless otherwise indicated

  On the contrary, percentages are percentages by weight. Mixed wind ingredients, before they are shaped, in order and in

  the conditions that the skilled person will adapt.

28411 01

EXAMPLES OF FORMULATION.

Example 1

UNIDOSE GEL

  . Active ingredient% wt _ Taurine 4 Grape seed extracts 40% OPC 4 Green tea extract 30% Catechins 6 Blackcurrant peel oil 10 Excipient Sugar syrup 50 Maltodextrin 17 Xanthan gum 0.8 Sodium benzoate 0.2 Water QSP 100 _ A dose of 200 to 400 ml per day can be taken.

Example 2

CAPSULE

  _ mg / capsule Taurine 50 Zinc gluconate 60 Wine extract (20% OPC) 200 Black currant oil 300 Glycerine 150 magnesium stearate 0.02 natural aroma Water QSP 900 mg

  One can take a trot of these capsules a day.

28411 01

Example 3

DRAGED TYPE FORMULATION

  mg / sucrose taurine 50 Grape extract (40% OPC) 50 Green extract (30% Catechin) 125 Zinc Sulfate (22.75%) 22. Microcrystalline Cellulose Extract 70 Encompress 60 Magnesium Stearate 3 Colloidal Silica Anhydride 1 _ Coating Agent _ Shellac 5 Talc 61 Sucrose 250 Polyvidone 6 Titanium Dioxide 0.3 Staining Agent 5

  This type of sucking can be taken 1 to 3 times a day.

Example 4

  A vitamin complex comprising 120 mg of vitamin C, 100 μg of vitamin E and 20 mg of zinc is added to the formulation of Example 1.

  6 mg of, B-carotene, for 200 ml of gel.

28411 01

Example 6

  A vitamin complex comprising 120 mg of vitamins C, 100 μg of vitamins E and 20 mg of zinc is added to the formulation of Example 1.

  6 mg of Iycopene per 200 ml of gel.

Example 7

  In the formulation of Example 3 is added a vitamin complex comprising 60 mg of vitamins C, 50 μg of vitamins E and 10 mg of zinc.

3 mg of Iycopene for a sucrose.

28411 01

Claims (20)

  1. Use of at least one fatty acid or an extract comprising, for the preparation of a food supplement useful in the   treatment or prevention of disorders of the pilo-sebaceous unit.   2. Use according to claim 1, for the preparation of a   dietary supplement useful to reduce or prevent seborrhee.   3. Use according to claim 1 or 2 for the preparation of a dietary supplement useful for reducing or preventing hair loss.   4. Use according to one of claims 1 to 3, for the   preparation of a dietary supplement useful for reducing or preventing   excessive metabolism of androgens in the skin.   5. Use according to one of claims 1 to 4, for the   preparation of a dietary supplement useful for reducing or preventing   The impact of testosterone on the pilo-sebaceous unit.   6. Use according to one of claims 1 to 5, characterized   in that the fatty acids are associated with taurine eVou or hypotaurine, or their acceptable salts in a composition valale, for the treatment or prevention of disorders of the pilo-sebaceous unit eVou de The alteration of the hair follicle.   7. Use according to one of claims 1 to 6, characterized   in that the fatty acid (s) selected from the essential polyunsaturated fatty acids n-6 and n-3, having between 18 and 22 carbon atoms,   carbon, as well as their esters and mixtures.   8. Use according to one of claims 1 to 7, characterized   in that the fatty acid (s) selected from linoleic acid, y-linolenic acid, linolenic acid, stearidonic acid, crocetin and acid, 8, 11, 14 eicosatetrainofque and mixtures thereof.   9. Use according to one of claims 1 to 8 characterized in   the daily dose of fatty acids is between 0.5 and   3500 mg / day, preferably 5 to 1500 mg / day. 28411 01   10. Use according to one of claims 1 to 9, characterized   in that the dose of n-6 fatty acids is between 0.5 and 2600 mg / day, preferably 5 to 1200 mg / day.   11. Use according to one of claims 1 to 10, characterized   in that the dose of n-3 fatty acids is between 0.5 and 2500 mg / day, preferably 5 to 360 mg / day.   12. Use according to one of claims 6 to 11, characterized   in that the daily dose of taurine eVou of hypotaurine and / or homotaurine or their acceptable salts, in taurine equivalent, is included   between 0.5 and 4000 mg / day, preferably 10 to 500 mg / day.   13. Use according to one of claims 6 to 12, characterized   in that the acceptable salts wind the alkaline or alkaline earth salts.   14. Use according to one of claims 1 to 13 characterized   in that the dietary supplement furthermore comprises at least one of the supplements chosen from vitamins C and E, zinc or its salts, selenium and at least one carotenoid, preferably a selected carotenode   among, B-carotene, Iycopene, zeaxanthin and lutein.   15. Composition for vale absorption of dietary supplement comprising at least one fatty acid or an extract comprising it in combination with taurine eVou hypotaurine eVou de   lythomoturin and / or their salts acceptable for the absorption.   16. Composition according to claim 15, characterized in that it comprises 0.01 to 30% by weight of taurine, eVu of hypotaurine and / or and / or thomotaurine of their acceptable salts, in association with 0.01 a. 10% by weight of fatty acids.   17. A composition according to claim 15 or 16, characterized in that it further comprises at least one of the supplements chosen from vitamins C and E, zinc or its salts, selenium and at least one carotenode, preferably a carotenoid. chosen from p-carotene,   Iycopene, zeaxanthin and lutein. 28411 01   18. Composition according to one of claims 15 to 17,   characterized in that the container is acceptable for a dietary supplement in the form of a dragee, gel, gel, emulsion, tablet,   capsule, buyable ampoule, powder, food bar or fortified food).   19. Cosmetic process for the treatment and prevention of disorders of the pilo-sebaceous unit by the administration of at least one fatty acid, or an extract possibly comprising it in combination with taurine eVou hypotaurine eVou the homotaurine, eVou their acceptable salts.   20. The method according to claim 19, wherein taurine, hypotaurine, homomotaurine or their acceptable salts are administered at a dose of 0.5 to 4000 mg per day in taurine equivalent, and at least one acid.